viernes, 27 de enero de 2023

FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma | FDA

FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma | FDA

No hay comentarios:

Publicar un comentario